CALIXAR team will be present at the virtual Biotech showcase, January 10–12, 2022 and January 17–19, 2022 to discuss partnering with other biopharmaceutical and life science actors and investors.
CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, Ion channels, Transporters, …). The company is currently investing in the extension of its pipeline of highly druggable membrane protein targets and native antigens. Within the next few years, CALIXAR will be able to offer to Pharma companies native and functional therapeutic targets validated and in a ready-to-discovery format.
CALIXAR wants to become a leader in the early discovery segment of drug development based on complex therapeutic targets (membrane proteins), a market predicted to be worth € 70 bn by 2025.
About the BIOTECH SHOWCASE:
The BIOTECH SHOWCASE is produced each year by Demy-Colton and EBD Group. This event allows companies to connect to thousands of peers from Startup, over Biotech and large Pharma. From early, mid to later stage. This 14th edition will be held online and will feature multiple tracks of curated presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings.
For more information: BIOTECH SHOWCASE